RECRUITING

Responses to Genetic Risk Modifier Testing Among Women with BRCA1/2 Mutations

Talk to us

Conditions

Genetic TestingBRCA1/2BRCA1/2 Mutations17-489

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.

Official Title

Responses to Genetic Risk Modifier Testing Among Women with BRCA1/2 Mutations

Quick Facts

Study Start:2018-01-04
Study Completion:2025-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03396341

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Female patient, age 25 years or older (given that women under this age are not generally recommended to receive BRCA1/2 genetic testing)
  2. * Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified
  3. * No personal history of breast cancer
  4. * English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
  1. * Previous receipt of any prophylactic mastectomy.
  2. * Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.
  3. * Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.

Contacts and Locations

Study Contact

Jada Hamilton, PhD, MPH
CONTACT
646-888-0049
hamiltoj@mskcc.org
Mark Robson, MD
CONTACT
646-888-5486

Principal Investigator

Jada Hamilton, PhD, MPH
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Dana Farber Cancer Institute (Data Collection Only)
Boston, Massachusetts, 02115
United States
Memorial Sloan-Kettering at Basking Ridge
Basking Ridge, New Jersey, 07920
United States
Memorial Sloan Kettering Commack
Commack, New York, 11725
United States
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
United States
Abramson Cancer Center at University of Pennsylvania Medical Center (Data Collection Only)
Philadelphia, Pennsylvania, 19104-4283
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Jada Hamilton, PhD, MPH, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-01-04
Study Completion Date2025-01

Study Record Updates

Study Start Date2018-01-04
Study Completion Date2025-01

Terms related to this study

Keywords Provided by Researchers

  • BRCA1/2 Mutations
  • 17-489

Additional Relevant MeSH Terms

  • Genetic Testing
  • BRCA1/2